Searched for
SGLT 2
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...- For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Heat waves demand more than just water for proper hydration; electrolytes intake necessary: ExpertsHealth experts warn that during heat waves, water alone is not enough for hydration. Excessive sweating depletes essential electrolytes lik...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Zydus Lifesciences hits the sweet spot after approval for generic diabetes drugZydus Lifesciences has achieved a significant milestone by obtaining tentative approval from the US FDA for Dapagliflozin Tablets. Designed...
- Standard Glass' exposure to single sector a key riskConsidering the annualised net profit for the six months ended September 2024 and equity after IPO, company demands a P/E multiple of 38.5 ...
- At over 10 cr, India’s diabetic population is surging, yet the country lags behind in prescribing new medicinesPriya Rao experienced confusion and worry after fainting and receiving different diabetic medications from two doctors. The first doctor fo...
- Torrent Pharmaceuticals partner with Boehringer Ingelheim to co-market diabetes, cardiovascular medicinesBoth companies entered into partnership for the sales and co-marketing of Empagliflozin and its combinations including Cospiaq (Empaglifloz...
- Glenmark launches unique fixed dose combination drug for diabetesThe Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter...
- Dr Reddy's Labs launches copy of BI drug; move may lead to legal battleUnder its brand Vicra, Dr. Reddy's is expected to sell the drug in India at less than a third of the price charged by Boehringer Ingelheim....
- Pharma may see a price war in good news for diabeticsGlenmark launches a drug at almost half the price of those offered by rivals.
- Glenmark Pharma launches anti-diabetes drug Remogliflozin in IndiaGlenmark said it will commercialise Remogliflozin in India under the brand names 'Remo' and 'Remozen'.
- Suffering from type 2 diabetes? New treatments can help control blood glucose levelOn World Diabetes Day, here's a list of new medications that will make life simpler for diabetics.
- Boehringer Igelheim aims for top slot with anti-diabetes drug launchWith Jardiance, BI has the advantage of significantly reducing cardiovascular risks associated with most patients with diabetes.
- Three new diabetes drugs come under the scanner of US drug regulatorThe other existing medicines for type-2 diabetes do not work through kidneys and rather use pancreas as a pathway.
Load More
